151 related articles for article (PubMed ID: 20101215)
1. Processing of CD109 by furin and its role in the regulation of TGF-beta signaling.
Hagiwara S; Murakumo Y; Mii S; Shigetomi T; Yamamoto N; Furue H; Ueda M; Takahashi M
Oncogene; 2010 Apr; 29(15):2181-91. PubMed ID: 20101215
[TBL] [Abstract][Full Text] [Related]
2. CD109 release from the cell surface in human keratinocytes regulates TGF-β receptor expression, TGF-β signalling and STAT3 activation: relevance to psoriasis.
Litvinov IV; Bizet AA; Binamer Y; Jones DA; Sasseville D; Philip A
Exp Dermatol; 2011 Aug; 20(8):627-32. PubMed ID: 21539622
[TBL] [Abstract][Full Text] [Related]
3. Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes.
Finnson KW; Tam BY; Liu K; Marcoux A; Lepage P; Roy S; Bizet AA; Philip A
FASEB J; 2006 Jul; 20(9):1525-7. PubMed ID: 16754747
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity.
Hagiwara S; Murakumo Y; Sato T; Shigetomi T; Mitsudo K; Tohnai I; Ueda M; Takahashi M
Cancer Sci; 2008 Oct; 99(10):1916-23. PubMed ID: 19016750
[TBL] [Abstract][Full Text] [Related]
5. CD109 attenuates TGF-β1 signaling and enhances EGF signaling in SK-MG-1 human glioblastoma cells.
Zhang JM; Murakumo Y; Hagiwara S; Jiang P; Mii S; Kalyoncu E; Saito S; Suzuki C; Sakurai Y; Numata Y; Yamamoto T; Takahashi M
Biochem Biophys Res Commun; 2015 Apr; 459(2):252-258. PubMed ID: 25724945
[TBL] [Abstract][Full Text] [Related]
6. Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression.
Hagikura M; Murakumo Y; Hasegawa M; Jijiwa M; Hagiwara S; Mii S; Hagikura S; Matsukawa Y; Yoshino Y; Hattori R; Wakai K; Nakamura S; Gotoh M; Takahashi M
Pathol Int; 2010 Nov; 60(11):735-43. PubMed ID: 20946523
[TBL] [Abstract][Full Text] [Related]
7. CD109-mediated degradation of TGF-β receptors and inhibition of TGF-β responses involve regulation of SMAD7 and Smurf2 localization and function.
Bizet AA; Tran-Khanh N; Saksena A; Liu K; Buschmann MD; Philip A
J Cell Biochem; 2012 Jan; 113(1):238-46. PubMed ID: 21898545
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a 60-kDa cell surface-associated transforming growth factor-beta binding protein that can interfere with transforming growth factor-beta receptor binding.
Piek E; Franzén P; Heldin CH; ten Dijke P
J Cell Physiol; 1997 Dec; 173(3):447-59. PubMed ID: 9369958
[TBL] [Abstract][Full Text] [Related]
9. The TGF-β co-receptor, CD109, promotes internalization and degradation of TGF-β receptors.
Bizet AA; Liu K; Tran-Khanh N; Saksena A; Vorstenbosch J; Finnson KW; Buschmann MD; Philip A
Biochim Biophys Acta; 2011 May; 1813(5):742-53. PubMed ID: 21295082
[TBL] [Abstract][Full Text] [Related]
10. Epidermal hyperplasia and appendage abnormalities in mice lacking CD109.
Mii S; Murakumo Y; Asai N; Jijiwa M; Hagiwara S; Kato T; Asai M; Enomoto A; Ushida K; Sobue S; Ichihara M; Takahashi M
Am J Pathol; 2012 Oct; 181(4):1180-9. PubMed ID: 22846721
[TBL] [Abstract][Full Text] [Related]
11. Soluble CD109 binds TGF-β and antagonizes TGF-β signalling and responses.
Li C; Hancock MA; Sehgal P; Zhou S; Reinhardt DP; Philip A
Biochem J; 2016 Mar; 473(5):537-47. PubMed ID: 26621871
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.
Kalo E; Buganim Y; Shapira KE; Besserglick H; Goldfinger N; Weisz L; Stambolsky P; Henis YI; Rotter V
Mol Cell Biol; 2007 Dec; 27(23):8228-42. PubMed ID: 17875924
[TBL] [Abstract][Full Text] [Related]
13. High-level expression of CD109 is frequently detected in lung squamous cell carcinomas.
Sato T; Murakumo Y; Hagiwara S; Jijiwa M; Suzuki C; Yatabe Y; Takahashi M
Pathol Int; 2007 Nov; 57(11):719-24. PubMed ID: 17922683
[TBL] [Abstract][Full Text] [Related]
14. TMEPAI, a transmembrane TGF-beta-inducible protein, sequesters Smad proteins from active participation in TGF-beta signaling.
Watanabe Y; Itoh S; Goto T; Ohnishi E; Inamitsu M; Itoh F; Satoh K; Wiercinska E; Yang W; Shi L; Tanaka A; Nakano N; Mommaas AM; Shibuya H; Ten Dijke P; Kato M
Mol Cell; 2010 Jan; 37(1):123-34. PubMed ID: 20129061
[TBL] [Abstract][Full Text] [Related]
15. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta receptor expression on human skin fibroblasts: dimeric complex formation of type I and type II receptors and identification of glycosyl phosphatidylinositol-anchored transforming growth factor-beta binding proteins.
Tam BY; Philip A
J Cell Physiol; 1998 Sep; 176(3):553-64. PubMed ID: 9699508
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of CD109 in the Epidermis Differentially Regulates ALK1 Versus ALK5 Signaling and Modulates Extracellular Matrix Synthesis in the Skin.
Vorstenbosch J; Nguyen CM; Zhou S; Seo YJ; Siblini A; Finnson KW; Bizet AA; Tran SD; Philip A
J Invest Dermatol; 2017 Mar; 137(3):641-649. PubMed ID: 27866969
[TBL] [Abstract][Full Text] [Related]
18. ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-beta/Smad-induced growth arrest of prostate cells.
Noda D; Itoh S; Watanabe Y; Inamitsu M; Dennler S; Itoh F; Koike S; Danielpour D; ten Dijke P; Kato M
Oncogene; 2006 Sep; 25(41):5591-600. PubMed ID: 16636667
[TBL] [Abstract][Full Text] [Related]
19. Association of down-regulation of CD109 expression with up-expression of Smad7 in pathogenesis of psoriasis.
Liu XX; Feng AP; He YM; Li Y; Wu Y; Lian X; Hu F; Li JW; Tu YT; Chen SJ
J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):132-136. PubMed ID: 26838754
[TBL] [Abstract][Full Text] [Related]
20. Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.
Sugano Y; Matsuzaki K; Tahashi Y; Furukawa F; Mori S; Yamagata H; Yoshida K; Matsushita M; Nishizawa M; Fujisawa J; Inoue K
Oncogene; 2003 Apr; 22(15):2309-21. PubMed ID: 12700666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
